Leapfrog Bio is taking a different approach to precision medicine and the treatment of cancer. Traditional approaches to developing cancer therapeutics focus on modifying the underlying disease-causing biology. This approach typically leads to an uncertain and years-long path of drug discovery, as well as the risks of unknown potential side effects once in the clinic. Leapfrog’s strategy leverages the company’s Precision PGx Platform™ to evaluate existing, clinically researched cancer small molecules to identify sensitizing mutations that result in cancer cell death. By using existing small molecules with well-described safety profiles, Leapfrog can move quickly into the clinical setting and reduce the risk, time, and cost of drug discovery. Visit leapfrog.bio.
